Edition:
United States

Merck KGaA (MKGAY.PK)

MKGAY.PK on OTC Markets Group

38.60USD
21 Jul 2017
Change (% chg)

$-0.44 (-1.13%)
Prev Close
$39.04
Open
$38.39
Day's High
$38.60
Day's Low
$38.33
Volume
3,123
Avg. Vol
8,053
52-wk High
$42.02
52-wk Low
$32.53

Latest Key Developments (Source: Significant Developments)

Merck KGaA and Pfizer: CHMP recommends approval of avelumab
Friday, 21 Jul 2017 07:38am EDT 

July 21 (Reuters) - MERCK KGAA ::EMA’S CHMP ISSUES POSITIVE OPINION FOR AVELUMAB FOR THE TREATMENT OF METASTATIC MERKEL CELL CARCINOMA.EUROPEAN COMMISSION WILL NOW REVIEW THE CHMP’S RECOMMENDATION, WITH A DECISION EXPECTED IN THE THIRD QUARTER OF 2017‍​.  Full Article

Merck KGaA refines Western European Life Science Production site network
Wednesday, 12 Jul 2017 09:43am EDT 

July 12 (Reuters) - MERCK KGAA ::REFINES WESTERN EUROPEAN LIFE SCIENCE PRODUCTION SITE NETWORK.CURRENT SITE NETWORK IN WESTERN EUROPE WILL BE REFINED, WHILE THE COMPANY INVESTS € 90 MILLION IN FOUR SITES IN GERMANY, SWITZERLAND AND FRANCE.THE OPERATIONS IN STEINHEIM, EPPELHEIM, HOHENBRUNN AND BERLIN (GERMANY) WILL BE RELOCATED AND SEQUENTIALLY CLOSED IN THE COURSE OF 2019 TO 2022.THERE WILL BE A NET IMPACT OF APPROXIMATELY 200 FEWER POSITIONS ACROSS THESE SITES UNTIL 2022.THE EXISTING HAMBURG (GERMANY) SITE WILL CONTINUE TO OPERATE AS BEFORE.  Full Article

EU medicines agency recommends approval of Aveo's kidney cancer drug
Friday, 23 Jun 2017 08:24am EDT 

June 23 (Reuters) - EU Medicines Agency::EU Medicines Agency recommendations for June 2017.EU Medicines Agency recommends approval of Merck KGAA multiple sclerosis drug.EU Medicines Agency recommends approval of Abbvie hepatitis C combination.EU Medicines Agency recommends approval of Novartis Kisqali drug for breast cancer.EU Medicines Agency recommends approval of Aveo drug for kidney cancer.EU Medicines Agency recommends approval of biosimilar drug by Samsung Bioepis UK for Abbvie's rheumatoid arthritis drug.  Full Article

EMA recommends approval of Merck's multiple sclerosis drug
Friday, 23 Jun 2017 07:43am EDT 

June 23 (Reuters) - EU Medicines Agency::EU Medicines Agency recommendations for June 2017.EU Medicines Agency recommends approval of Merck KGAA multiple sclerosis drug.EU Medicines Agency recommends approval of Abbvie Hepatitis C combination.EU Medicines Agency recommends approval of Novartis Kisqali drug for breast cancer.EU Medicines Agency recommends approval of Aveo drug for kidney cancer.EU Medicines Agency recommends approval of Abbvie biosimilar drug for rheumatoid arthritis.  Full Article

Effector Therapeutics to collaborate with Pfizer and Merck to evaluate immuno-oncology combination in microsatellite stable colorectal cancer
Tuesday, 20 Jun 2017 08:00am EDT 

June 20 (Reuters) - Merck Kgaa :Effector Therapeutics to collaborate with Pfizer and Merck KGAA to evaluate a novel immuno-oncology combination in microsatellite stable colorectal cancer.Effector Therapeutics - cos plan to initiate Phase 2 study to evaluate EFT508 in combination with avelumab in microsatellite stable relapsed or refractory CRC patients.Effector Therapeutics - Pfizer and Merck KGAA will share clinical study costs with effector.  Full Article

Human Longevity says agreement with Merck KGaA, Darmstadt, Germany to engage in cancer biomarker discovery in advanced melanoma
Thursday, 15 Jun 2017 11:00am EDT 

June 15 (Reuters) - Human longevity Inc : :Human longevity - signed agreement with merck kgaa, darmstadt, germany which operates its biopharmaceutical business as emd serono in u.s. And canada.Human longevity - as part of deal, co's have started joint pilot project to identify treatment response biomarker signatures in patients with advanced melanoma.Human longevity inc says financial terms of deal were not disclosed.  Full Article

Ablynx to receive 15 million euros milestone payment
Monday, 22 May 2017 01:00am EDT 

May 22 (Reuters) - ABLYNX NV ::NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT.ABLYNX ANNOUNCED THAT IT HAS COMPLETED PREPARATION OF A PRE-CLINICAL PACKAGE FOR A NOVEL NANOBODY® (ALX-1141) IN OSTEOARTHRITIS.AS PART OF ONGOING COLLABORATION BETWEEN ABLYNX AND MERCK KGAA <<>>, MERCK HAS ACCEPTED PRE-CLINICAL PACKAGE AND THIS HAS TRIGGERED A EUR 15 MILLION MILESTONE PAYMENT TO ABLYNX.MERCK IS NOW RESPONSIBLE FOR FURTHER CLINICAL DEVELOPMENT OF MOLECULE.  Full Article

Merck KGaA says losing some market share in liquid crystals to new Chinese rivals
Thursday, 18 May 2017 04:14am EDT 

May 18 (Reuters) - Merck KGaA :CFO says seeing no signs of weakening demand at life science division.CFO says losing some market share in liquid crystals to new Chinese rivals.CFO says liquid crystal market share will level out over time at about 50-60 percent, down from clearly more than 60 percent over last 1-2 years.  Full Article

Merck KGaA's Pergoveris fertility pen gets EU approval
Wednesday, 10 May 2017 07:22am EDT 

May 10 (Reuters) - Merck KGaA :Says European Commission grants approval for Merck’s new Pergoveris pen for fertility treatment.  Full Article

U.S. FDA grants accelerated approval to Avelumab for Urothelial Carcinoma
Tuesday, 9 May 2017 12:22pm EDT 

May 9 (Reuters) - U.S. FDA::U.S. Food and Drug Administration grants accelerated approval to avelumab for urothelial carcinoma.  Full Article

BRIEF-Merck KGaA and Pfizer: CHMP recommends approval of avelumab

* EMA’S CHMP ISSUES POSITIVE OPINION FOR AVELUMAB FOR THE TREATMENT OF METASTATIC MERKEL CELL CARCINOMA